Image Source: AsiaOne
Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro GlobeNewswireNovember 29, 2021Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022 Inventory build continues in anticipation of EUA in second half of 2022, with 4 million doses available for distribution over the next two years
Source: AsiaOne